Omnes Capital's investments

Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.

Offered in SaaS mode to marketing teams looking to adopt a data-driven approach while remaining highly agile, the AB Tasty solution helps e-commerce sites, interactive service providers and media to improve their conversion rate, irrespective of whether their digital presence consists of web sites, mobile sites or native applications. A holder of the French Tech Pass and the BPI Excellence seal of quality, AB Tasty ranks among the most innovative businesses operating in the French web ecosystem.

Established in 2011, Bankin' has revolutionised the management of bank accounts using a mobile app that simplifies and clarifies money management. It offers an intelligent look at bank accounts and expense items (automatic categorisation) as well as monthly budgets. It also allows steering your money using a forecast end of month balance and automatic alerts of risks of overdraft.

Founded in 2001, Oxatis has developed a Software/SaaS platform enabling SMEs and micro-companies to set up and run web-based shop window or ecommerce sites. Oxatis offers a full range of solutions covering all the services required to set up and operate an ecommerce website, including online software, shopping basket, hosting, secure payment, order management, inventory management, domain names and links with the leading market players.

Created in March 2014, Horama is developing new gene therapies for the treatment of hereditary retinopathies pigmentosa, which are orphan ophthalmological diseases. The company gathers the expertise of internationally renowned scientific experts in the field of ophthalmologic gene therapies. Its ambition is to help slow down visual loss and even improve the visual function by injecting a specific viral vector based on adeno-associated viruses (AAV). Horama’s scientific founding team (Nantes and Montpellier, France) is the first one in France to have completed an ophthalmology gene therapy study in 2011.

Launched in 2013 by two sisters, Hannah Oiknine and Sarah Azan, Babbler is a platform for exchanging content and news in real time between communications and media professionals (editors, journalists, bloggers etc.).
With the growing number of new channels of influence, the company offers a new approach to media relations drawing on the logic of social media: factoring in the ideas of community, engagement and data.
The tool acts as a real facilitator that can be used to optimise interaction between advertisers, communications/PR agencies and the media with a matching system on registering.
Journalists and influencers have access to targeted news based on their centres of interest, while advertisers benefit from live reports on monitoring of their publications and exchanges with journalists.
Around 4,000 journalists and influencers, for whom registration is free, and more than 300 advertisers use the platform.

Intersec designs innovative software enabling companies to leverage their Big Data. Our disruptive technology crunches and consolidates huge amounts of data coming from heterogeneous network equipment and IT, and turns them into actionable insights in real-time. Applications range from Customer Base Management, mass-scale Location-Based Services, Fraud Management and Business Analytics.